Tetanus - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 85 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Tetanus - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Tetanus - Pipeline Review, H2 2014', provides an overview of the Tetanus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tetanus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Tetanus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tetanus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tetanus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Tetanus Overview 9
Therapeutics Development 10
Pipeline Products for Tetanus - Overview 10
Pipeline Products for Tetanus - Comparative Analysis 11
Tetanus - Therapeutics under Development by Companies 12
Tetanus - Therapeutics under Investigation by Universities/Institutes 14
Tetanus - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Tetanus - Products under Development by Companies 19
Tetanus - Products under Investigation by Universities/Institutes 20
Tetanus - Companies Involved in Therapeutics Development 21
Sanofi 21
GlaxoSmithKline plc 22
Daiichi Sankyo Company, Limited 23
Takeda Pharmaceutical Company Limited 24
Biological E. Limited 25
Novartis AG 26
Zydus Cadila Healthcare Limited 27
Green Cross Corporation 28
LG Life Sciences, Ltd. 29
Bharat Biotech International Limited 30
Sinovac Biotech Ltd. 31
Serum Institute of India Limited 32
Indian Immunologicals Limited 33
Beijing Minhai Biotechnology Co., Ltd 34
Sanofi Pasteur SA 35
Tetanus - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
diphtheria + tetanus toxoids + acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DtwP-HB-Hib (liq) Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis (inactivated) + haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GC-1107 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DTwP-HBV-Hib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VN-0103 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GSK-217744 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TAK-361S - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + tetanus+ pertussis vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + pertussis + tetanus vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + pertussis + tetanus vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Tetanus Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Toxoid Vaccine for Diptheria and Tetanus - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Vaccine for Diptheria, Tetanus and Pertussis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GC-3111A - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DTwP-IPV - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DTaP Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Diphtheria + Tetanus + Pertussis (Acellular) Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DPT-H-HiB Vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Tetanus Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tetanus vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DTwP-Hep B-IPV-Hib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DTwP-IPV + Hib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
DTwP + Hib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Tetanus - Recent Pipeline Updates 75
Tetanus - Dormant Projects 76
Tetanus - Product Development Milestones 77
Featured News & Press Releases 77
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 77
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 77
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 78
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 79
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 79
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 80
Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 80
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 81
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 82
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85

List of Tables
Number of Products under Development for Tetanus, H2 2014 10
Number of Products under Development for Tetanus - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Tetanus - Pipeline by Sanofi, H2 2014 21
Tetanus - Pipeline by GlaxoSmithKline plc, H2 2014 22
Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 23
Tetanus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 24
Tetanus - Pipeline by Biological E. Limited, H2 2014 25
Tetanus - Pipeline by Novartis AG, H2 2014 26
Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 27
Tetanus - Pipeline by Green Cross Corporation, H2 2014 28
Tetanus - Pipeline by LG Life Sciences, Ltd., H2 2014 29
Tetanus - Pipeline by Bharat Biotech International Limited, H2 2014 30
Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2014 31
Tetanus - Pipeline by Serum Institute of India Limited, H2 2014 32
Tetanus - Pipeline by Indian Immunologicals Limited, H2 2014 33
Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 34
Tetanus - Pipeline by Sanofi Pasteur SA, H2 2014 35
Assessment by Monotherapy Products, H2 2014 36
Assessment by Combination Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Tetanus Therapeutics - Recent Pipeline Updates, H2 2014 75
Tetanus - Dormant Projects, H2 2014 76